Phase 2
N=23
Study of Nicotinamide in Early Onset Preeclampsia
Pre-Eclampsia · Pregnancy Related
Bottom Line
View on ClinicalTrials.gov: NCT03419364 ↗Enrolled (actual)
23
Serious AEs
0.0%
Results posted
Sep 2022
Primary outcome: Primary: Change in Mean Arterial Blood Pressure (MAP) — 0; 2; 4 mmHg
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- nicotinamide (Drug)
- Age
- Adult · 18+ yrs
- Sex
- Female
- Sponsor
- University of North Carolina, Chapel Hill
- Primary completion
- Aug 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Mean Arterial Blood Pressure (MAP) |
0; 2; 4 | — |
| SECONDARY Number of Participants With Alanine Aminotransferase (ALT) =/> 3x Upper Limit of Normal (ULN) |
— | — |
| SECONDARY Number of Participants With Aspartate Aminotransferase (AST) =/> 3x Upper Limit of Normal (ULN) |
— | — |
| SECONDARY Number of Participants With Maternal Side Effects |
0; 0; 0 | — |
| SECONDARY Percentage of Women Maternal Abdominal Tenderness |
0; 0; 0 | — |
| SECONDARY Percentage of Women With Headache Unrelieved by Oral Analgesics |
33; 0; 0 | — |
| SECONDARY Percentage of Women With Hematocrit Decrease of More Than 3% |
44 | — |
| SECONDARY Percentage of Women With Less Than 500 cc Urine Output in 24 Hours |
— | — |
| SECONDARY Percentage of Fetuses With Category III Non Stress Test Results |
— | — |
| SECONDARY Percentage of Fetuses With Biophysical Profile < 6 |
— | — |
| SECONDARY Mean Peak Nicotinamide Level |
12701.7; 13279.7; 16314.1 | — |
| SECONDARY Mean Trough Concentration Nicotinamide Administration |
479.2; 1490.7; 1991.2 | — |
Summary
Phase II Study of 2.5 gm of nicotinamide, given daily in 3 divided doses, to measure effect on maternal blood pressure in women with early onset preeclampsia and to determine peak and trough levels of nicotinamide. We will compare peak and trough levels in healthy non-pregnant and healthy pregnant participants.
Eligibility Criteria
Diagnosis and Inclusion Criteria
- Maternal age 18-55 years
- Singleton pregnancy with no known fetal anomalies
- Early-onset preeclampsia OR early-onset severe gestational hypertension defined as:
- Early-onset: between 24 weeks 0 days and -33 weeks 3 days, based on menstrual dating confirmed by first or second trimester ultrasound OR second trimester ultrasound if menstrual dating unavailable;
- Preeclampsia:
- New onset hypertension and proteinuria, with systolic BP > 140 mm Hg and/or diastolic BP > 90 mm Hg on two occasions 6 hours apart and > 300 mg proteinuria on 24 hour urine collection OR urine P/C ratio >0.3;
- New onset hypertension and NO proteinuria, with systolic BP > 140 mm Hg and/or diastolic BP > 90 mm Hg on two occasions 6 hours apart and one or more of the following: serum creatinine >1.1 mg/dL or doubling from baseline ,or central nervous system symptoms or visual changes
- Severe preeclampsia defined as new onset systolic BP > 160 mm Hg and/or diastolic BP > 105 with proteinuria as above or or without proteinuria and one or more of the following criteria listed above
- Candidate for expectant management for at least 48 hours
- Deemed clinically stable by primary clinician and candidate for expectant management (delayed delivery) for at least 48 hours;
- Maternal liver function tests 100,000 mm³
- Planned expectant management
- Pre-existing medical diseases such as hypertension, diabetes, endocrine disorders, gastrointestinal diseases, are well controlled
- Fetal well-being established by estimated fetal weight > 5th %tile; normal amniotic fluid volume (MVP > 2 cm); normal Umbilical Artery (UA) Dopplers; or reactive Non Stress Test (NST) or Biophysical Profile (BPP) > 6
- Delivery not anticipated within 48 hours of enrollment
Exclusion Criteria
- Pre-existing renal disease (creatinine > 1.5 mg/dL)
- Any pre-existing medical condition that would increase risk for liver toxicity (e.g. hepatitis B or C; HIV; Isoniazid (INH) use)
- Eclampsia; cerebral edema on CT/MRI; headache unrelieved by analgesics
- Evidence of liver dysfunction (LFTs > 2x ULN)
- Thrombocytopenia (platelets < 100,000 mm³)
- Pulmonary edema
- HELLP syndrome
- Evidence of fetal compromise: Estimated Fetal Weight (EFW) < 5th percentile; or BPP < 6; or absent or reverse diastolic UA blood flow; or oligohydramnios (MVP < 2 cm)
- Placental abruption defined as unexplained vaginal bleeding
- Preterm labor defined as regular contractions and cervical change
- Any condition deemed by the investigator to be a risk to mother or fetus in completion of the study
- Any condition deemed by the investigator to require delivery within 48 hours
Data sourced from ClinicalTrials.gov (NCT03419364). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.